On February 18, 2025, Arcus Biosciences, Inc. (the "Company") reported that, as of December 31, 2024, it had approximately $992 million in cash, cash equivalents and marketable securities (Press release, Arcus Biosciences, FEB 18, 2025, View Source [SID1234650330]). This estimate of its cash, cash equivalents and marketable securities balance is preliminary and subject to completion of its financial closing procedures, including the completion of management’s reviews. Accordingly, the unaudited preliminary cash, cash equivalents and marketable securities balance set forth above reflects its preliminary estimate with respect to such information, based on information currently available to management, and may vary from its actual financial position as of December 31, 2024. Further, this preliminary estimate is not a comprehensive statement or estimate of its financial results or financial condition as of December 31, 2024.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Item 8.01 Other Events.
The contents of Item 2.02 above are also incorporated by reference into this Item 8.01.
Gilead Opt-in Decision
On February 18, 2025, the Company announced that the time-limited exclusive option of Gilead Sciences, Inc. ("Gilead") to the casdatifan program has expired without exercise by Gilead. As a result, Gilead has no future rights to casdatifan; the Company retains full global development and commercial rights, subject to Taiho Pharmaceutical Co., Ltd.’s option right for its territory, which is limited to Japan and certain other Asian countries (excluding China).
ARC-20 Data Release
On February 15, 2025, the Company reported new data from three cohorts of its ARC-20 study for casdatifan in patients with metastatic clear cell renal cell carcinoma, most of whom had progressed on at least two prior lines of therapy, including both an anti-PD-1 and a VEGFR tyrosine kinase inhibitor therapy. The new data include median progression-free survival and overall response rate ("ORR") for the cohort evaluating 50mg of casdatifan twice a day ("BID"), and ORR for the cohorts evaluating 50mg of casdatifan once daily ("QD") and 100mg QD. The patient population was heavily pretreated; more than half (52-59%) of subjects received at least three prior lines of therapy and approximately one quarter (24-29%) had received at least four prior lines of therapy. Most patients (70-76%) had an International Metastatic Renal Cell Carcinoma Database Consortium risk factor of intermediate or poor.
With a data cut-off of January 3, 2025 (the "DCO"), most patients (81-87%) experienced disease control with either a partial response or stable disease. The median duration of response had not been reached, with all but two of the 26 responders across all three cohorts still on treatment.
No unexpected safety signals were observed at the time of the DCO, and casdatifan had an acceptable and manageable safety profile across all doses. Across all three cohorts, one patient discontinued treatment as a result of anemia and two due to hypoxia. A summary of the efficacy and safety results is below:
50mg BID
(n=32) 50mg QD
(n=28) 100mg QD Tablet
(Go-forward dose)
(n=27)
Efficacya
Median Follow-up 15 months 12 months 5 monthsb
Median Progression-Free
Survival [95% CI]
9.7 months
(5.5, NE)
NE
(6.8, NE)
NE
Confirmed ORR per
RECIST v1.1 [95% CI]
25% (8)c
[11.5, 43.4]
32% (9)c
[15.9, 52.4]
33% (9)
[16.5, 54.0]
Best Overall Responsed:
Complete Response
Partial Response
Stable Disease
Progressive Disease
31% (10)
0
31% (10)
50% (16)
19% (6)
32% (9)
4% (1)
29% (8)
54% (15)
14% (4)
33% (9)
0
33% (9)
52% (14)
15% (4)e
Median Time to Response 2.8 months 4.1 months 1.6 months
Disease Control Rate
[95% CI]
81%
[63.6, 92.8]
86%
[67.3, 96.0]
85%
[66.3, 95.8]
Safetyf
Any Serious Treatment-Emergent
Adverse Events (TEAEs)
related to casdatifan
3% (1) 10% (3) 7% (2)
Grade ≥3 TEAEs related to
casdatifan
Anemia
Hypoxia
42% (14)
9% (3)
32% (10)
7% (2)
17% (5)
10% (3)
CI=confidence interval, NE=not estimable
a Efficacy-evaluable population for this expansion cohort is defined as all eligible participants who received any study treatment and have at least one post-baseline efficacy assessment, or who discontinue study treatment due to progressive disease or death.
b Majority of patients (n=21) were still on treatment at time of DCO.
c In the 50mg BID cohort, one unconfirmed responder remains on treatment. In the 50mg QD cohort, one unconfirmed responder became a confirmed responder after the DCO, increasing the cORR to 32%.
d Unconfirmed best overall response.
e Includes two patients with radiological progressive disease and two patients who had clinical progression before the first scan.
f The safety-evaluable population included all dose expansion enrolled patients who received any amount of any study treatment.